News|Articles|April 8, 2025

Expert Insights: At APhA 2025, Pharmacists Reaffirmed Their Essential Role in Patient Care

Author(s)Kennedy Ferruggia, Associate Editor, Luke Halpern, Associate Editor

Pharmacy professionals gathered at the American Pharmacists Association 2025 Annual Meeting and Exposition and discussed critical insights in interviews with Pharmacy Times®.

As the future of the pharmacy profession continues to rapidly evolve, it remains critical for stakeholders in the field to stay informed and educate their colleagues on the key advancements and consensuses forming around them. To that end, pharmacists gathered at the American Pharmacists Association (APhA) 2025 Annual Meeting and Exposition in Nashville, Tennessee, to discuss the latest trends and clinical insights in pharmacy and health care.

Related to this article

October 28th, 2026

Kidney Week 2026: Pharmacists' Growing Role in Kidney Care

From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.

October 27th, 2026

Pharmacists Can Help Overcome Therapeutic Inertia in CKM Care

Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026

IgG4-Related Kidney Disease: Why It’s Missed and How to Treat It

October 27th, 2026

Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.

October 23rd, 2026

Enlicitide Cuts LDL-C Regardless of Kidney Function

In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.

October 23rd, 2026

Kidney Week 2026: What to Know for Nephrology's Biggest Meeting

Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.

3d illustration of narrowed blood vessel due to atherosclerosis, Symptoms of high cholesterol in the blood

October 28th, 2026

PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease

Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.

October 27th, 2026

GLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKD

Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.

October 26th, 2026

GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026

Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.